Dianthus Therapeutics Inc
Veridion Score
Composite trend over time
Why is DNTH moving today?
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DNTH.
DNTH insider activity
Dianthus Therapeutics Inc
2 insiders bought in the last 90 days
Net selling: -$31.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-06-01 | Randhawa Simrat | Insider | sell | $91.37 | 4,159 | 4,000 | $380K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat | Insider | sell | $90.72 | 16,943 | 8,159 | $1.5M | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat | Insider | sell | $89.72 | 5,428 | 25,102 | $487K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat | Insider | buy | $22.07 | 9,375 | 30,530 | $207K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat | Insider | buy | $21.77 | 6,249 | 21,155 | $136K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 54 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moDNTH contract awards, year to date.
Public federal awards linked to this ticker.
DNTH lobbying filings, year to date.
Registered lobbying filings matched to Dianthus Therapeutics Inc.